ThomasPrebetMD

PubMed

• 1 citations
  Luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): primary analysis of...
  Matteo Giovanni Della Porta, Guillermo Garcia-Manero, Valeria Santini, Amer M Zeidan, Rami S Komrokji
  The Lancet. Haematology. 2024-09-01
• 3 citations
  Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials.
  Pau Montesinos, Amir T Fathi, Stéphane de Botton, Eytan M Stein, Amer M Zeidan
  Blood Advances. 2024-05-28
• Somatic gene mutation patterns and burden influence outcomes with enasidenib in relapsed/refractory IDH2-mutated AML.
  Alberto Risueño, Wendy L See, Iryna Bluemmert, Stéphane de Botton, Courtney D DiNardo
  Leukemia Research. 2024-05-01

Abstracts/Posters

• The PRIME Trial: PARP Inhibition in IDH Mutant Effectiveness Trial. a Phase II Study of Olaparib in Isocitrate Dehydrogenase (IDH) Mutant Relapsed/Refractory Acute Mye...
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Immune Checkpoint Inhibitor Therapy for Acute Myeloid Leukemia and Higher-Risk Myelodysplastic Syndromes: A Single-Center Experience
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Olutasidenib (FT-2102), an IDH1m Inhibitor As a Single Agent or in Combination with Azacitidine, Induces Deep Clinical Responses with Mutation Clearance in Patients wi...
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• PARP Inhibitors Are Effective in IDH1/2 Mutant MDS and AML Resistant to Targeted IDH Inhibitors
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Ivo-Nivo: A Phase II Study of the IDH1 Inhibitor Ivosidenib (AG-120) in Combination with the Checkpoint Blockade Inhibitor Nivolumab for Patients with IDH1 Mutated Rel...
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Biomarker Modulation By Mivebresib (ABBV-075) +/_ Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloi...
  Thomas Prebet, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Phase 1 Study of the IDH1m Inhibitor FT-2102 As a Single Agent in Patients with IDH1m Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• FT-2102, an IDH1m Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Ayndrome (MDS): Results from a Phase 1 Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018